LaBrosse Nicole 4
4 · HALOZYME THERAPEUTICS, INC. · Filed Sep 23, 2025
Insider Transaction Report
Form 4
LaBrosse Nicole
SVP, CHIEF FINANCIAL OFFICER
Transactions
- Sale
Common Stock
2025-09-22$77.83/sh−1,913$148,883→ 22,393 total - Sale
Common Stock
2025-09-22$78.67/sh−314$24,701→ 22,079 total
Footnotes (3)
- [F1]The sales reported on this Form 4 were effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on June 11, 2025.
- [F2]Represents a weighted average sales price per share. These shares were sold at prices ranging from $77.34 to $78.32. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
- [F3]Represents a weighted average sales price per share. These shares were sold at prices ranging from $78.37 to $79.18. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.